Amgen Inc. (AMGN)
(Delayed Data from NSDQ)
$255.71 USD
+0.58 (0.23%)
Updated Apr 16, 2021 04:00 PM ET
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
| Zacks Rank | Definition | Annualized Return |
|---|---|---|
| 1 | Strong Buy | 25.41% |
| 2 | Buy | 19.02% |
| 3 | Hold | 10.72% |
| 4 | Sell | 6.46% |
| 5 | Strong Sell | 3.06% |
| S&P | 500 | 11.04% |
Zacks Rank Education - Learn about the Zacks Rank
Zacks Rank Home - Zacks Rank resources in one place
Zacks Premium - The only way to fully access the Zacks Rank
3-Hold of 5 3
The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.
The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.
| Value Score | A |
|---|---|
| Growth Score | A |
| Momentum Score | A |
| VGM Score | A |
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
Zacks Style Scores Education - Learn more about the Zacks Style Scores
B Value D Growth D Momentum C VGM
The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.
The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.
Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank
View All Zacks #1 Ranked Stocks
Zacks News
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva
Stock Market News for Apr 16, 2021
by Zacks Equity Research
Benchmark hit new records on Thursday as rebound in consumer spending and a buoyant jobs market attested economic recovery along with better-than-expected Q1 earnings reports.
UNHPositive Net Change NVDANegative Net Change BACPositive Net Change CNegative Net Change AMDNegative Net Change CRMNegative Net Change XLNXNegative Net Change AMGNPositive Net Change OKTANegative Net Change
finance medical tech-stocks
Top Stock Reports for Abbott, salesforce & BHP
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Abbott Laboratories (ABT), salesforce.com (CRM), and BHP Group (BHP).
BHPNegative Net Change ABTPositive Net Change CRMNegative Net Change AMGNPositive Net Change DHRPositive Net Change ZMNegative Net Change
computers industrial-products internet medical
AbbVie (ABBV) Seeks Skyrizi Approval for Psoriatic Arthritis
by Zacks Equity Research
AbbVie (ABBV) files regulatory applications with the FDA and the EMA, seeking approval for a new indication of Skyrizi - psoriatic arthritis.
BIIBNegative Net Change NVSPositive Net Change AMGNPositive Net Change ABBVPositive Net Change
pharmaceuticals
Should Invesco Defensive Equity ETF (DEF) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DEF
DEFPositive Net Change DGXPositive Net Change EBAYPositive Net Change AMGNPositive Net Change QQQPositive Net Change VUGPositive Net Change
dividend etf expenses holdings index market-capitalization
Top Research Reports for JPMorgan, Verizon & Chevron
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase (JPM), Verizon Communications (VZ), and Chevron (CVX).
JPMPositive Net Change VZPositive Net Change CVXNegative Net Change PFEPositive Net Change QCOMPositive Net Change AMGNPositive Net Change
communications finance medical oil-energy pharmaceuticals
AbbVie's (ABBV) Rinvoq Dermatitis sNDA Review Gets Delayed
by Zacks Equity Research
The FDA extends the review period of AbbVie's (ABBV) label expansion application for Rinvoq in atopic dermatitis by three months.
BIIBNegative Net Change PFEPositive Net Change AMGNPositive Net Change ABBVPositive Net Change
pharmaceuticals
Sanofi (SNY) Gets FDA Approval for Sarclisa Label Expansion
by Zacks Equity Research
Sanofi's (SNY) Sarclisa gets FDA approval to treat multiple myeloma patients who have received one to three prior lines of therapy in combination with Kyprolis and dexamethasone.
SNYPositive Net Change BMYPositive Net Change AMGNPositive Net Change TBIONegative Net Change
pharmaceuticals
Amgen (AMGN) to Boost Inflammation Pipeline With Rodeo Buyout
by Zacks Equity Research
Amgen (AMGN) inks an agreement to acquire privately held company, Rodeo Therapeutics Corporation, to boost its inflammation portfolio.
BMYPositive Net Change AMGNPositive Net Change RGENNegative Net Change NBRVNegative Net Change
biotechs
Merck's (MRK) Breast Cancer sBLA for Keytruda Gets CRL (Revised)
by Zacks Equity Research
FDA issues a complete response letter to Merck's (MRK) sBLA seeking label expansion of Keytruda as neoadjuvant and adjuvant treatment for patients with triple-negative breast cancer. A phase III study in this indication is ongoing.
PFEPositive Net Change MRKPositive Net Change GSKPositive Net Change AMGNPositive Net Change
pharmaceuticals
Merck (MRK) Keytruda Gets CHMP Nod for First-Line Bladder Cancer
by Zacks Equity Research
Merck (MRK) is seeking approval for label expansion of Keytruda in Europe to include first-line treatment of certain patients with advanced or metastatic urothelial carcinoma.
PFEPositive Net Change MRKPositive Net Change GSKPositive Net Change AMGNPositive Net Change
pharmaceuticals
Akebia (AKBA) Files NDA for Vadadustat for Anemia Due to CKD
by Zacks Equity Research
Akebia (AKBA) submits new drug application for vadadustat to treat anemia due to chronic kidney disease in adult patients who are on dialysis as well as who are not on dialysis.
GSKPositive Net Change AMGNPositive Net Change AKBANegative Net Change FGENPositive Net Change
medical
Merck's (MRK) Breast Cancer sBLA for Keytruda Gets CRL
by Zacks Equity Research
FDA issues a complete response letter to Merck's (MRK) sBLA seeking label expansion of Keytruda as neoadjuvant and adjuvant treatment for patients with triple-negative breast cancer. A phase III study in this indication is ongoing.
PFEPositive Net Change MRKPositive Net Change GSKPositive Net Change AMGNPositive Net Change
pharmaceuticals
Merck (MRK) Gets FDA Nod for Keytruda in Esophageal Cancer
by Zacks Equity Research
The FDA approves Merck's (MRK) anti-PD-1 therapy, Keytruda in combination with chemotherapy, for the first-line treatment of esophageal and gastroesophageal junction carcinoma.
PFEPositive Net Change MRKPositive Net Change GSKPositive Net Change AMGNPositive Net Change
pharmaceuticals
Glaxo (GSK) Begins Late-Stage Severe Eosinophilic Asthma Study
by Zacks Equity Research
Glaxo (GSK) is developing an anti-IL-5 monoclonal antibody candidate, GSK3511294 - engineered for high affinity and long-acting suppression of IL-5 function - for treating severe asthma patients.
TEVANegative Net Change AZNNegative Net Change GSKPositive Net Change AMGNPositive Net Change
pharmaceuticals
AbbVie (ABBV) Down as FDA Extends Review of Rinvoq sNDA
by Zacks Equity Research
The FDA extends the review period of AbbVie's (ABBV) label expansion application for Rinvoq in active psoriatic arthritis by three months.
BIIBNegative Net Change PFEPositive Net Change AMGNPositive Net Change ABBVPositive Net Change
pharmaceuticals
Merck (MRK) VHL-Linked Kidney Cancer Drug Gets FDA Priority Tag
by Zacks Equity Research
The FDA grants Merck's (MRK) NDA for belzutifan priority review status to treat von Hippel-Lindau disease-associated renal-cell carcinoma.
AZNNegative Net Change PFEPositive Net Change MRKPositive Net Change AMGNPositive Net Change
pharmaceuticals
The Zacks Analyst Blog Highlights: NIKE, Broadcom, Amgen, BlackRock and Estee Lauder
by Zacks Equity Research
The Zacks Analyst Blog Highlights: NIKE, Broadcom, Amgen, BlackRock and Estee Lauder
NKEPositive Net Change ELPositive Net Change BLKNegative Net Change AMGNPositive Net Change AVGONegative Net Change
consumer-discretionary consumer-staples finance medical semiconductor tech-stocks
Top Research Reports for Nike, Broadcom & Amgen
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including NIKE (NKE), Broadcom (AVGO), and Amgen (AMGN).
NKEPositive Net Change MCDPositive Net Change ELPositive Net Change BLKNegative Net Change AMGNPositive Net Change AVGONegative Net Change
consumer-staples finance medical restaurants retail semiconductor
Biotech Stock Roundup: AMGN's Acquisition, ACAD's Regulatory Update & More
by Zacks Equity Research
The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Amgen (REGN), Acadia (ACAD) and Gilead (GILD).
GILDPositive Net Change AMGNPositive Net Change FPRXPositive Net Change ACADNegative Net Change IMVTNegative Net Change
biotechs pharmaceuticals
Amgen (AMGN) to Add Stomach Cancer Drug With Five Prime Buyout
by Zacks Equity Research
Amgen (AMGN) inks a $1.9-billion deal to acquire clinical-stage biotech, Five Prime Therapeutics, to boost its oncology pipeline.
BMYPositive Net Change AMGNPositive Net Change SGENNegative Net Change FPRXPositive Net Change
biotechs
ETFs to Tap Amgen's Drive for Cancer Deal
by Sweta Killa
Amgen (AMGN) has agreed to buy Five Prime Therapeutics (FPRX) for $1.9 billion.
BMYPositive Net Change AMGNPositive Net Change IBBPositive Net Change FPRXPositive Net Change BBHPositive Net Change PJPPositive Net Change IEIHPositive Net Change
biotechs etfs medical pharmaceuticals
Amgen (AMGN) Down 5.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AMGNPositive Net Change
earnings earnings-estimates earnings-performance earnings-report earnings-trend revenue zacks-consensus-estimate
Biohaven (BHVN) Q4 Earnings Miss, Nurtec Uptake Promising
by Zacks Equity Research
Biohaven's (BHVN) recently approved migraine drug, Nurtec ODT, continues to demonstrate strong launch uptake.
LLYPositive Net Change AMGNPositive Net Change ABBVPositive Net Change BHVNNegative Net Change
biotechs earnings
Radius' (RDUS) Q4 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Radius (RDUS) reports a wider loss but beats sales estimates in the fourth quarter.
ENDPPositive Net Change LLYPositive Net Change AMGNPositive Net Change RDUSNegative Net Change
biotechs earnings pharmaceuticals
Biotech Stock Roundup: REGN's Drug Approval & Pipeline Updates From AMGN, BLUE
by Zacks Equity Research
The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Regeneron (REGN), Amgen (AMGN) and bluebird (BLUE).
REGNPositive Net Change AMGNPositive Net Change CRTXPositive Net Change BLUENegative Net Change ACIUNegative Net Change
biotechs